Sana Biotechnology, Inc. (NASDAQ:SANA) Given Average Rating of "Moderate Buy" by Brokerages

Key Points

• Analysts give Sana Biotechnology a “Moderate Buy” consensus: seven rate the stock a buy, one a strong buy, one a hold and one a sell. The average 12-month price target is $9.33.
• Recent analyst actions were mixed, with Bank of America cutting its price target to $6 while maintaining a buy rating, and TD Cowen upgrading the stock to strong buy.
• Sana reported quarterly EPS of $(0.13), beating the consensus estimate of $(0.15). Institutional investors and hedge funds own approximately 88.23% of the company’s shares.

Sana Biotechnology, Inc. (NASDAQ:SANA - Get Free Report) has received an average recommendation of "Moderate Buy" from the ten brokerages that are covering the company, MarketBeat reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. The average 12 month price objective among brokers that have covered the stock in the last year is $9.3333.

Several equities research analysts recently commented on the company. Weiss Ratings raised Sana Biotechnology from a "sell (e+)" rating to a "sell (d-)" rating in a report on Thursday, July 23rd. Wall Street Zen lowered shares of Sana Biotechnology from a "hold" rating to a "sell" rating in a research note on Monday, July 20th. Bank of America dropped their price objective on shares of Sana Biotechnology from $7.00 to $6.00 and set a "buy" rating for the company in a report on Friday, August 14th. Finally, TD Cowen raised shares of Sana Biotechnology to a "strong-buy" rating in a research note on Monday, August 24th.

Institutional Investors Weigh In On Sana Biotechnology

Large investors have recently modified their holdings of the company. Rockefeller Capital Management L.P. increased its position in Sana Biotechnology by 74.3% during the 4th quarter. Rockefeller Capital Management L.P. now owns 9,588 shares of the company's stock worth $39,000 after purchasing an additional 4,088 shares in the last quarter. Walleye Capital LLC purchased a new position in Sana Biotechnology during the second quarter worth approximately $35,000. Callan Family Office LLC purchased a new stake in shares of Sana Biotechnology during the 2nd quarter worth about $43,000. Royal Bank of Canada raised its position in Sana Biotechnology by 76.8% in the first quarter. Royal Bank of Canada now owns 12,285 shares of the company's stock valued at $35,000 after purchasing an additional 5,338 shares during the period. Finally, Leonteq Securities AG acquired a new position in shares of Sana Biotechnology during the first quarter worth $43,000. 88.23% of the stock is owned by institutional investors and hedge funds.

Sana Biotechnology Stock Up 2.2%

Shares of NASDAQ SANA opened at $3.20 on Tuesday. The firm has a market cap of $957.96 million, a PE ratio of -4.21 and a beta of 2.12. The business has a fifty day simple moving average of $3.57 and a two-hundred day simple moving average of $3.38. Sana Biotechnology has a twelve month low of $2.61 and a twelve month high of $6.55.

Sana Biotechnology (NASDAQ:SANA - Get Free Report) last posted its quarterly earnings data on Monday, August 10th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.15) by $0.02. On average, research analysts expect that Sana Biotechnology will post -0.72 earnings per share for the current year.

About Sana Biotechnology

Sana Biotechnology, Inc is a clinical-stage biotechnology company focused on developing engineered cells and gene therapies for the treatment of serious diseases. The company's approach is designed to create therapeutic cells that can be delivered to patients without requiring individualized manufacturing, potentially broadening access to cell-based medicines.

Sana is developing technologies intended to address key challenges in cell and gene therapy, including immune rejection, targeted delivery of genetic material and the production of engineered cells at scale.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.